Key facts
- Celloid’s last known valuation is $24.1M (Mar 2026).
- It has raised $8.8M; the latest was Later Stage VC ($6.2M) in Mar 2026.
- Notable investors include Tech Incubator Program for Startup, FuturePlay, Schmidt (South Korea), POSTECH Holdings, Seoul Biohub.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Celloid
- ·The full record, as it builds
Funding rounds
No funding rounds for Celloid are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Celloid
Developer of a cell structure technology designed to provide the optimal 3-dimensional cell culture method. The company's technology allows the quality-controlled long-term culture of organoids with homogeneity and reproducibility, and continues to facilitate the use of organoids in drug development and diagnostics, further in regenerative medicine, enabling healthcare organizations to move towards automated culture.
- Sector
- Healthcare
- HQ
- Pohang, South Korea
- Founded
- 2021
- Employees
- 15
- Website
- celloid.co.kr/
- Ownership
- Privately Held (backing)
Celloid doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Celloid shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Celloid in its N-PORT filings yet. We sweep new filings monthly.